In September 2025, TG Therapeutics presented updated six-year data from the ULTIMATE I & II Phase 3 trials of BRIUMVI® (ublituximab-xiiy) for relapsing multiple sclerosis at the ECTRIMS annual meeting ...
Qure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback